PharmaBlock buys plant in China from Porton Pharma

Nanjing, China-based PharmaBlock has acquired a manufacturing site from Porton Pharma Solutions in Shangyu, China. (PharmaBlock)

China’s PharmaBlock Sciences says it has acquired a GMP-compliant manufacturing facility from Porton Pharma Solutions in Shangyu, China, where it will make intermediates.

The 1,436,000-square-foot site, located in a state-level chemical industry park in Shangyu, Zhejiang Province, has been operating as a multipurpose, GMP-compliant facility since December 2015, according to a press release. Terms of the deal were not disclosed.

The facility is equipped with reactors with 300 L to 6300 L in capacity and can handle a range of chemistry synthesis and enabling processes, PharmaBlock said. The Chinese firm intends to begin construction on a second phase this year which will allow it to manufacture APIs at the site.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

“The acquisition of this site provides additional GMP capacity and supplements our existing assets in Shandong Dezhou site,” PharmaBlock chairman Minmin Yang said in a statement.

The release said that PharmaBlock also has a new process R&D center outside of Philadelphia, Pennsylvania. It said phase I at the 7,000-square-foot facility is now in full operation.